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Abstract 
Background: Amphiphilic poly(N‑isopropylacrylamide)‑block‑poly(ε‑caprolactone) (PNiPAAm‑b‑PCL) copolymers 
were synthesized by ring‑opening polymerization to form thermosensitive micelles as nanocarriers for bioimaging 
and carboplatin delivery.
Results: The critical micelle concentration increased from 1.8 to 3.5 mg/l following the decrease of the PNiPAAm 
chain length. The copolymers revealed a lower critical solution temperature (LCST) between 33 and 40°C. The copoly‑
mers self‑assembled to form spherical particles of 146–199 nm in diameter. Carboplatin in micelles exhibited a slower 
release at 37°C relative to that at 25°C due to the gel layer formation on the micellar shell above the LCST. The micelles 
containing dye or carboplatin were intravenously injected into the rats for in vivo bioimaging and drug biodistribu‑
tion. The bioimaging profiles showed a significant accumulation of micelles in the lungs. The micelles could mini‑
mize the reticuloendothelial system (RES) recognition of the dye. In vivo biodistribution demonstrated an improved 
pulmonary accumulation of carboplatin from 2.5 to 3.4 μg/mg by the micelles as compared to the control solution. 
Carboplatin accumulation in the heart and kidneys was reduced after encapsulation by the micelles.
Conclusion: This study supports the potential of PNiPAAm‑b‑PCL micelles to passively target the lungs and attenuate 
RES uptake and possible side effects.
Keywords: Copolymer, Micelle, Thermosensitivity, Carboplatin, Lung, Passive targeting
© 2015 Lee et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Polymeric micelles are the nanoparticles developed by 
the self-assembly of amphiphilic polymers. They are use-
ful for entrapping lipophilic drugs for targeted antican-
cer drug delivery via the enhanced permeation retention 
(EPR) effect. The micelles are also found to prolong the 
circulation time of drugs, reduce the adverse effect, and 
improve the therapeutic index [1, 2]. Polymeric micelles/
nanoparticles are the biomedical nanostructures with 
the most commercialized products after liposomes [3]. 
Biodegradable polymers are preferred as the nanomateri-
als for therapeutic application. Poly(ε-caprolactone) (PCL) 
is one of the biodegradable polymers widely used in nan-
oparticles for bioimaging, drug delivery, and tissue scaf-
folding [4]. This polyester is approved by the US Food and 
Drug Administration (USFDA) because of its biocompat-
ibility, biodegradation, and nontoxicity in nature [5]. Due 
to its lipophilic characteristics, pendent functionalization 
with other polymers to produce the copolymers is highly 
needed to achieve the suitable hydrophilicity, bioadhe-
sion, and drug encapsulation for biological use [6].
Poly(N-isopropylacrylamide) (PNiPAAm) is a ther-
mosensitive polymer with a lower critical solution tem-
perature (LCST) of ~32°C. It is extensively employed to 
form the temperature-responsive copolymers with other 
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polymers [7]. Some investigations synthesize the copol-
ymers of PNiPAAm and PCL conjugates for their bio-
compatibility and temperature sensitivity [6, 8, 9]. For 
temperature-triggered drug delivery, it is generally recog-
nized that the thermosensitive micelles show a slow drug 
release at temperatures below the LCST, whereas heating 
above the LCST results in the destruction of the micellar 
structure and the expulsion of the entrapped drug. How-
ever, in the case of the conjugates of PNiPAAm and PCL, 
a gel layer on the micellar shell is formed after trigger-
ing the thermoresponsiveness [10, 11]. This layer creates 
a diffusion barrier to enhance the sustained drug release.
Although the copolymers related to combined PNiPAAm 
and PCL were developed previously, no in vivo data proved 
their usefulness for biological application. Herein we blocked 
the lipophilic segments of PCL to the hydrophilic block 
of PNiPAAm to prepare a core–shell micelle. We aimed to 
develop a multifunctional nanocarrier for bioimaging and 
controlled drug delivery. The diblock copolymers were syn-
thesized with different PNiPAAm and PCL block lengths. 
The micelles were fabricated using a dialysis technique to 
determine the physicochemical properties. Carboplatin was 
used as the model anticancer drug in this study. The passive 
targeting of the micelles to organs was examined. The safety 
of the micelles was evaluated at the cell level, including the 
lactic dehydrogenase (LDH) leakage of human neutrophils 
and the viability of 293T and HaCaT cells.
Results
Synthesis of PNiPAAm‑b‑PCL
PNiPAAm-b-PCL diblock copolymers were synthe-
sized by ring-opening polymerization of CL with 
hydroxyl-terminated PNiPAAm as shown in Figure  1. 
Three copolymers with different monomer numbers, 
including PNiPAAm8-b-PCL20, PNiPAAm9-b-PCL15, 
and PNiPAAm14-b-PCL59, were conjugated in this 
work. Figure  2A illustrates the representative 1H NMR 
spectrum of PNiPAAm8-b-PCL20. Observations 
showed typical signals of PNiPAAm blocks at 1.15 ppm 
(Ha, –CH(CH3)2), 3.88–4.08  ppm (Hb, –CH(CH3)2), 
1.35–1.83  ppm (Hc, –CH2–CH–), and 2.15–2.33  ppm 
(Hd, CH2–CH–). The signals at 2.15–2.33 ppm were also 
assigned to the protons of PCL (Hg, –COCH2–). The 
chemical shifts at 1.35–1.83  ppm were ascribed to the 
protons of PCL (Hh, Hi, and Hj, –CH2–). The peaks at 
3.88–4.08 ppm corresponded to –OCH2– moiety in PCL 
(Hk).
Figure 2B displays the FTIR spectra of PNiPAAm8, CL, 
and the grafted PNiPAAm8-b-PCL20. The PNiPAAm 
spectrum showed the characteristic peaks at 3,306 cm−1 
(N–H), 2,973 cm−1 (C–H), and 1,651 cm−1 (amide C=O). 
The CL spectrum revealed the signals at 2,934  cm−1 
(C–H), 1,730 cm−1 (ester C=O), and 1,170 cm−1 (C–O). 
In the FTIR spectrum of the grafted copolymer, the exist-
ence of the peaks from PNiPAAm and CL confirmed an 
effective synthesis of PNiPAAm-b-PCL. The absorption 
peak at 1,188  cm−1 became stronger in the spectrum 
of the copolymer as compared to that of CL, indicating 
that there existed a number of C–O groups introduced 
by PCL backbone. The molecular weights of the diblock 
copolymers are measured by GPC as shown in Additional 
file 1: Table  S1. The molecular weight of PNiPAAm8-
b-PCL20, PNiPAAm9-b-PCL15, and PNiPAAm14-
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Figure 1 Synthetic procedures of PNiPAAm and PNiPAAm‑b‑PCL.
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The traces of GPC exhibited a unimodal peak, demon-
strating a narrow molecular weight distribution of the 
copolymers.
Characterization of PNiPAAm‑b‑PCL micelles
The excitation spectra of pyrene in copolymer solu-
tion were examined to calculate the values of the critical 
micelle concentration (CMC). The distinguishing prop-
erty of the excitation spectra was a red shift from 331 
to 334  nm upon pyrene partitioning into the lipophilic 
core of the micelles. Figure  3 depicts the intensity ratio 
(I334/I331) of pyrene versus the logarithm of the copoly-
mer concentration (log C). The I334/I331 ratio showed 
a substantial increase at a particular concentration, 
suggesting the pyrene entrapment into the micelles. 
Additional file 1: Table S1 summarizes the CMC values 
of different copolymers. It could be observed that the 
CMC decreased following the increase of the PNiPAAm 
chain length. The copolymer with the longest PCL length 
(PNiPAAm14-b-PCL59) demonstrated the lowest CMC 
(1.75 mg/l) among the copolymers.
We had characterized the LCST of the copolymer 
micelles by recognizing the transmittance change. As 
shown in the left panel of Figure  3b, a sharp transmit-
tance reduction is visualized at a determined tempera-
ture. This indicates a phase transition from a transparent 
and clear solution to a formation of suspension contain-














































Figure 2 The representative 1H NMR spectrum of PNiPAAm8‑b‑PCL20 (A) and FTIR spectra of PNiPAAm8 (line a), CL (line b) and PNiPAAm8‑b‑PCL20 
(line c) (B).
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As shown in Additional file 1: Table S1, 33, 35, and 40°C, 
respectively, are the LCST of PNiPAAm8-b-PCL20, PNi-
PAAm9-b-PCL15, and PNiPAAm14-b-PCL59.
Additional file 1: Table S1 summarizes the size, poly-
dispersity, and zeta potential of the micelles. At 25°C, 
PNiPAAm8-b-PCL20 revealed a mean diameter of 
146  nm. The average size was increased following the 
increase of the PNiPAAm chain length. The polydisper-
sity of the three micelles ranged between 0.22 and 0.25, 
expressing a narrow size distribution. The zeta potential 
of the micelles was anionic, with no significant difference 
among the surface charge of the three nanosystems. The 
negative zeta potential of the micelles is a result of lone-
pair electrons in the grafted PNiPAAm.
Stability of PNiPAAm‑b‑PCL micelles
PNiPAAm displays a coil-to-globule transition tempera-
ture at 32°C, which can undergo a conversion from room 
temperature to body temperature (37°C). This LCST is 
feasible for clinical application. PNiPAAm8-b-PCL20 
was selected as the model copolymer for further inves-
tigation because its LCST (33°C) is so close to 32°C. 
Figure 4a illustrates the TEM image of the PNiPAAm8-
b-PCL20 micelles. A spherical core–shell morphology 
was observed. The self-assembled micelles were well dis-
tributed as individual particles. The micellar size shown 
in the TEM image was smaller than that determined by 
the laser-scattering technique. A broad size range was 
also observed by TEM. This is attributed to the detection 
of the dehydrated solid state by TEM, whereas a hydro-
dynamic diameter was detected by laser scattering. The 
micelles were water-swollen in the hydrodynamic state.
The stability of the PNiPAAm8-b-PCL20 micelles 
was examined by incubating the nanosystems at 25°C 
for 3  weeks. Average diameter and zeta potential were 
used as the indicators to evaluate the micellar stability. 
As illustrated in Figure 4b, the size and zeta potential of 
PNiPAAm8-b-PCL20 showed no significant change dur-
ing the 3  weeks. This suggests that the thermosensitive 
micelles are stable for at least 3 weeks; thus further appli-
cation can be promised.
The change of physicochemical properties of micelles  
as a function of temperature
The size and zeta potential of PNiPAAm8-b-PCL20 were 
assessed by varying the temperature from 25 to 40°C. 
As shown in Additional file 1: Table S2, the diameter 
of the micelles increased from 146 to 370 nm when the 
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Figure 3 Plots of I334/I331 intensity ratio versus the logarithm of copolymer concentration for PNiPAAm‑b‑PCL (a) and phase transition curves (b) of 
PNiPAAm‑b‑PCL from 25 to 50°C.
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temperature was raised from 25 to 36°C. A further size 
augmentation to 567  nm was found as the temperature 
was increased to 40°C. The polydispersity of the micelles 
at 40°C was 1.00, indicating a very broad distribution of 
the different sizes in the nanosystems. The zeta potential 
remained constant after the heating.
Carboplatin release from micelles
To explore the effect of temperature on carboplatin deliv-
ery, the drug-release experiment was performed at the 
temperatures of 25 and 37°C. Figure  5 depicts the per-
centage of released carboplatin plotted as a function of 
time. A 4% DMSO in double-distilled water was used as 
the control vehicle for dissolving carboplatin. As shown 
in Figure 5a, a two-phase release pattern was observed for 
carboplatin released from the control solution. Carbopl-
atin exhibited an initial burst from the control, then grad-
ually leveled off after 10 h. About 65% of the carboplatin 
had been released by 24 h. The control solution showed a 
faster release of carboplatin above the LCST than below 
the LCST. This discrepancy was not significant. Encapsu-
lation of carboplatin into PNiPAAm8-b-PCL20 micelles 
revealed a more controllable drug release compared to 
the control as observed in Figure 5b. The burst carbopl-
atin release was alleviated by the micellar incorporation. 
Carboplatin was continuously released from the micelles 
within 24  h. Approximately 10% of the carboplatin was 
released at the end of the experiment (24 h). When the 
temperature was elevated from 25 to 37°C, the drug 
release was suppressed to a significant degree.
Weeks

















Figure 4 Transmission electron microscopic micrograph of PNiPAAm8‑b‑PCL20 micelles (a) and storage stability of PNiPAAm8‑b‑PCL20 micelles 
determined by average size and zeta potential (b). Each value represents the mean ± SD (n = 4).
Figure 5 In vitro cumulative amount‑time profiles across cellulose membrane of carboplatin release from control solution (a) and PNiPAAm8‑
b‑PCL20 micelles (b) assessed by Franz diffusion cell at 25 and 37°C. Each value represents the mean ± SD (n = 4).
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Cytotoxicity of the micelles
The preliminary examination on the cytotoxicity of 
PNiPAAm8-b-PCL20 was performed in various cells. 
Figure  6 shows the results. Neutrophils are the main 
leukocytes (50–70%) in systemic circulation. The cyto-
toxicity of neutrophils can be associated with disruption 
of membrane integrity as indicated by LDH. As demon-
strated in Figure 6a, micelle intervention does not show 
cytotoxicity against human neutrophils at all concentra-
tions tested (1.5–48  μg/ml). Human embryonic kidney 
cells (293T) and keratinocytes (HaCaT) were chosen 
as the model systems to evaluate the cytotoxicity of 
micelles. Figure 6b, c exhibit the cell viability (%) of 293T 
and HaCaT in the presence of micelles, respectively. The 
copolymer micelles did not elicit a significant cytotoxicity 
to both cell lines compared to the nontreatment control.
Organ bioimaging
The possible application of the copolymer micelles was 
further assessed by organ bioimaging and drug distri-
bution in rats. The rats intravenously administered with 
DiR solution or micelles were sacrificed 2  h postinjec-
tion, and the organs were then harvested and imaged 
as shown in Figure 7. DiR solution clearly resided in the 
reticuloendothelial system (RES), including the liver and 
spleen (Figure 7a). Some signals were shown in the brain, 
lungs, kidneys, and gastrointestinal tract. However, the 
intensity of these organs was much less than that of RES. 
The bright signal of the liver was also achieved by micelle 
administration (Figure 7b). A negligible signal was visu-
alized in the spleen treated with micelles, indicating a 
lower RES uptake of micelles than the control. A lower 
level of intensity was also noted in the brain treated with 
micelles compared to DiR solution. It is noticeable that, 
in contrast to the control, the micelles induced a much 
greater accumulation in the lungs. An extensive distribu-
tion of near IR signal was observed in the lungs treated 
with micelles. The near IR intensity in the kidneys and 
gastrointestinal tract was comparable between the two 
groups.
Biodistribution of carboplatin
To investigate the delivery effectiveness of the micelles, 
in vivo biodistribution of carboplatin in the organs of 
interest was assessed. Additional file 1: Table  S3 com-
pares carboplatin accumulation in the organs at 2 h fol-
lowing intravenous injection of the control solution 
and micelles. The carboplatin uptake by the brain, liver, 
and spleen was comparable between the aqueous solu-
tion and the micelles. For the PNiPAAm8-b-PCL20 
micelles, 3.35 μg/mg carboplatin was distributed in the 
lungs, which was a higher accumulation (p < 0.05) than 
in the control (2.5 μg/mg). Inclusion within the micelles 
allowed a significantly lower drug heart uptake (1.04 μg/
mg) compared to the control (1.83  μg/mg) (p  <  0.05). 
Lower carboplatin concentration (p < 0.05) in the kidneys 
was detected at 2  h postinjection of micelles (0.74  μg/
mg) compared to aqueous solution (1.45 μg/mg).
Discussion
Polymeric modification by copolymer strategy is advan-
tageous for biomedical use because of the possibility of 
modulating drug release, mechanical properties, and bio-
compatibility [12]. We had synthesized PNiPAAm-b-PCL 
diblock copolymers consisting of thermosensitive moi-
ety and biodegradable polyester backbones. PNiPAAm-
b-PCL formed self-assembly micelles containing a core 
made from PCL blocks surrounded by PNiPAAm ther-
moresponsive coronal chains. The spectra of 1H NMR 
and FTIR confirmed a successful coupling between PNi-
PAAm and PCL.
The copolymer with the largest PCL block (PNi-
PAAm14-b-PCL59) showed the lowest CMC. This could 
be due to the stronger lipophilic interaction and reduced 
solvency resulting from the more lipophilic core in the 
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Figure 6 The LDH release of neutrophils (a) and the cell viability (%) of 293T cells (b) and HaCaT cells (c) treated by PNiPAAm8‑b‑PCL20 micelles. 
Each value represents the mean ± SD (n = 3).
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15] also suggest that the increased lipophilic segment 
or decreased hydrophilic segment in PNiPAAm-based 
copolymers resulted in the lower CMC. However, this 
concept cannot explain the higher CMC of PNiPAAm8-
b-PCL20 compared to PNiPAAm9-b-PCL15 since the 
former copolymer possessed less hydrophilic moiety and 
more lipophilic moiety than the latter copolymer. This 
could be due to the greater molecular weight of PNi-
PAAm8-b-PCL20 than PNiPAAm9-b-PCL15. The high 
molecular mass of the copolymer may lead to the high 
threshold for forming micelles. The experimental results 
indicate that PNiPAAm-b-PCL exhibited a lower CMC 
as compared to most of the low-molecular-weight sur-
factants such as sodium lauryl sulfate (2.3 g/l) [16]. This 
suggests a strong tendency of the copolymers toward 
self-assembly of micelles. The low CMC also demon-
strates the thermodynamic stability of the micelles and 
the prevention of premature drug release from micelles 
[17].
The copolymers would be hydrated below the LCST 
due to the production of hydrogen binding between the 
copolymers and water. The PNiPAAm moiety becomes 
lipophilic above the LCST because of the lipophilic 
interaction among the isopropyl groups. This leads to 
the fusion of the micelles. The size enlargement of the 
micelles as a function of temperature can confirm the 
production of aggregates. The hydrophilicity level of PNi-
PAAm can largely influence the transition temperature of 
the thermosensitive copolymers. Previous studies [9, 18] 
indicate that the LCST of PNiPAAm-b-PCL-b-PNiPAAm 
triblock copolymers increases with the increase in the 
chain length of the PNiPAAm block, which is due to the 
increased hydrophilicity of the copolymers. Our LCST 
results correlated with this tendency. PNiPAAm14-
b-PCL59 showed an LCST value of 40°C. The increment 
of the PNiPAAm-based copolymer molecular weight 
and the degree of polymerization leads to the shift of the 
LCST to a higher temperature [15, 19]. The diameter of 
PNiPAAm8-b-PCL20 micelles increased to 567  nm at 
40°C due to the aggregation. This size is still acceptable 
in the bloodstream without the risk of clogging. There 
would be finite aggregation of the micelles in a dilute sys-
tem [20].
With a copolymer concentration prepared at 50-fold 
CMC, the copolymer with the largest PCL block (PNi-
PAAm14-b-PCL59) displayed the greatest micelle size 
(199  nm). The extension of the average diameter with 
increasing PCL length originates from the increment of 
lipophilic degree and the capacity in the micellar core 
[10, 21]. Nevertheless, this cannot explain the larger 
size of PNiPAAm9-b-PCL15 compared to PNiPAAm8-
b-PCL20. This could be attributed to the longer length of 
the PNiPAAm block having the more-hydrated and bulk-
ier shell [6, 16].
The hydrophilicity of the shell of PNiPAAm-based 
micelles has been found to be weakened once the tem-
perature is increased above the LCST [17, 22]. This can 
result in the partial destruction of the micellar structure, 
leading to the facile drug release at body temperature. 
This was not the case in this study since PNiPAAm-
b-PCL micelles exhibited a slower drug release upon 
heating to 37°C. The burst carboplatin release from the 
control solution was also restrained after incorporation 
into the micelles. Choi et al. [10] demonstrated that the 
Figure 7 Fluorescence imaging of organs under Pearl® Impulse sys‑
tem at near IR wavelength after a 2‑h injection of DiR control solution 
(a) and DiR‑loaded PNiPAAm8‑b‑PCL20 micelles (b).
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phase transition causes a sol to gel transformation of 
PNiPAAm-b-PCL copolymers. An additional gel layer 
around the particulate surface is created above the LCST, 
contributing to the diffusion barrier for drug passage. It 
is postulated that the PNiPAAm block turns lipophilic 
above the LCST. This phase transition causes a thicken-
ing of the lipophilic segment in the micellar shell [23]. 
The drug-release process from the micelles includes the 
drug escape from the micellar core, and then the diffu-
sion across the shell and the drug partitioning into the 
external phase occurs. The enlarged lipophilic shell pre-
vents drug delivery into the aqueous phase and promotes 
drug entrapment in the micelles [20]. Almost no further 
carboplatin release was shown after an initial burst. Car-
boplatin inclusion in the micelles produced a prolonged 
and continuous release. This suggests a sustained delivery 
of carboplatin by micellar entrapment. This effect is espe-
cially important when administering the nanocarriers 
into circulation. The biodegradable copolymers always 
suffer from hydrolytic and enzymatic erosion in systemic 
circulation [24]. This may lead to a quick drug release 
before targeting the specific organs. PNiPAAm-b-PCL 
micelles may ameliorate this drawback.
Free DiR exhibited an extensive distribution in RES 
[25]. Our in vivo bioimaging profiles confirmed this 
trend. The RES uptake accelerated elimination in the 
body. DiR accommodated in micelles had avoided 
the recognition by RES, especially in the spleen. The 
nanoparticle size of <200 nm minimizes the degree of 
RES uptake and lessens renal excretion, thus increas-
ing the possible targeting to specific organs or tumors 
[26]. The micelles developed in this study fulfilled 
this criterion. The thermosensitive micelles contain-
ing DiR still showed a significant accumulation in the 
liver. This was because of the critical role of the liver 
in PCL-based micelle clearance [27]. The micelles 
showed a negligible delivery to the brain, indicat-
ing a difficult passage across the blood–brain barrier 
(BBB). A significant accumulation of micelles was 
found in the lungs, demonstrating a passive targeting 
to this organ. It is proposed that the prolonged circula-
tion of the micelles due to RES bypassing leads to an 
opportunity to target specific organs such as the lungs. 
The lungs serve in the circulation as the first filter for 
xenobiotics [28]. This effect is unlikely to be mediated 
by RES. Pulmonary vasculature contains extensive vas-
cular networks with 25–30% of the total endothelial 
surface of the body [29]. The unique feature promotes 
the PNiPAAm-b-PCL micelle deposition in the lungs. 
The transition from the hydrophilic to the lipophilic 
corona of thermosensitive micelles at body tempera-
ture also accelerates micellar escape from the circula-
tion to the peripheral tissues.
Since the DiR-loaded micelles largely accumulated 
in the lungs, the nanocarriers delivered a higher carbo-
platin amount to this organ as compared to the control. 
Micellar loading partly decreased the RES uptake of DiR. 
However, this effect was minor for carboplatin. It is inter-
preted that DiR and carboplatin are different molecules 
with different metabolism pathways. The tendency to 
escape RES by micelles is dependent on the loaded mol-
ecules. The thermoresponsive micelles enhanced carbo-
platin uptake by the lungs but decreased the distribution 
in the heart and kidneys. This approach ameliorated drug 
delivery to targeted tissues and reduced accumulation to 
nontargeted tissues, an improvement that would help to 
avoid side effects. A major problem of anticancer drug 
administration is the clearance of the renal system [30]. 
Free carboplatin is a small molecule with a molecular 
mass of 371 Da. Nanoparticles with a size of 10–200 nm 
can prevent the rapid renal excretion of some antican-
cer drugs [31]. The negative surface charge of micelles 
is beneficial in the blood for evading micellar aggrega-
tion caused by adsorption of plasma proteins [32]. The 
copolymer micelles with a very low CMC demonstrate 
an excellent stability in the systemic circulation owing to 
slower micelle dissociation than occurs with small molec-
ular surfactant nanoparticles [11]. The physicochemical 
characteristics of PNiPAAm-b-PCL micelles suggest that 
this thermosensitive nanocarrier is stable in the circula-
tion, making it conducive to slowly delivering the drug 
over a long period.
The experimental results suggested a passive target-
ing of PNiPAAm-b-PCL micelles to the lungs, which was 
preferred for pulmonary disease or lung cancer therapy. 
Active targeting such as antibody or peptide conjugation 
to nanoparticles is an efficient way to deliver the drug to 
targeted sites; nevertheless, the antibody-ligand nano-
carriers are accompanied by a toxicity concern [33, 34]. 
For example, the exogenous antibodies can contribute 
to antibody-mediated acute lung injury [35]. The cost of 
the antibody is also high. Passive targeting by micelles 
is another option for efficient drug delivery to the lungs. 
The micelles exhibited no toxicity toward mammalian 
cells, including 293T and HaCaT. The results of the LDH 
assay demonstrated a favorable blood compatibility of 
micelles. The micelles developed in the present study can 
be regarded as safe. The next investigation for evaluating 
the applicability of the carboplatin-loaded micelles is the 
evaluation of tumor targeting and anticancer efficacy in 
the lungs.
Conclusion
Diblock copolymer PNiPAAm-b-PCL was synthesized 
and characterized with the aim of combining thermo-
sensitivity and biocompatibility. The grafted copolymers 
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self-assembled into spherical micelles with an LCST of 
33–40°C. The CMC of the copolymers was in the range of 
1.8–3.5 mg/l, which decreased as the length of the PNi-
PAAm chains grew. The micelles formed a gel layer on 
the shell above the LCST, producing a delayed and sus-
tained diffusion of carboplatin. We assessed neutrophil, 
293T, and HaCaT cytotoxicity in response to the micelles, 
and we detected no toxicity to these cells. The improved 
lung delivery and decreased RES uptake of the micelles 
enabled passive targeting to the lungs. The avoidance of 
the undesirable organ accumulation and toxicity associ-
ated with the drug was also achieved. The amphiphilic 
copolymer micelles fabricated in this study appear prom-
ising as nanocarriers for carboplatin.
Methods
Materials
N-Isopropylacrylamide (NiPAAm), ε-caprolactone (CL), 
carboplatin, azobisisobutyronitrile (AIBN), and toluene 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine 
iodide (DiR) was supplied by ATT Bioquest (Sunnyvale, 
CA, USA). Benzoyl peroxide (BPO) came from Shimakyu 
(Osaka, Japan). 2-Mercaptoethanol was provided by Avan-
tor (Center Valley, PA, USA). N,N-dimethylformamide 
(DMF) and tetrahydrofuran (THF) were purchased from 
Mallinckrodt (St. Louis, MO, USA). Tin(II) 2-ethylhex-
anoate (Sn(Oct)2) was from Strem Chemicals (Newbury-
port, MA, USA).
Synthesis of PNiPAAm
A determined amount of NiPAAm (6 g for PNiPAAm8-
b-PCL20, 4  g for PNiPAAm9-b-PCL15, and 2  g for 
PNiPAAm14-b-PCL59), 2-mercaptoethanol (0.2  g for 
PNiPAAm8-b-PCL20, 0.09  g for PNiPAAm9-b-PCL15, 
and 0.13  g for PNiPAAm14-b-PCL59), and 2% (w/v) 
BPO were added to a round-bottom flask under nitro-
gen atmosphere. THF (15 ml) was then added to the flask 
with stirring for 24 h. The crude product was purified by 
ether in the presence of THF to remove the unreacted 
monomer and initiators. The product was purified twice 
to obtain the white powder of PNiPAAm. Figure 1 shows 
the scheme of PNiPAAm synthesis.
Synthesis of PNiPAAm‑b‑PCL
The diblock copolymer of PNiPAAm-b-PCL was pre-
pared through a ring-opening polymerization of CL with 
PNiPAAm in toluene by utilizing Sn(Oct)2 as the cata-
lyst. PNiPAAm (5.92  g for PNiPAAm8-b-PCL20, 5.1  g 
for PNiPAAm9-b-PCL15, and 5.0  g for PNiPAAm14-
b-PCL59), CL (10.3  g for PNiPAAm8-b-PCL20, 9.1  g 
for PNiPAAm9-b-PCL15, and 20.1  g for PNiPAAm14-
b-PCL59), and 1.5% (w/v) Sn(Oct)2 were refluxed in 
toluene (30 ml) under a nitrogen stream for 24 h. After 
this reaction, the mixture was concentrated by rotary 
evaporator. The product was dissolved in chloroform and 
precipitated into ether/n-hexane (1:5). This procedure 
was repeated twice. The purified copolymer was dried 
under vacuum conditions. Figure  1 demonstrates the 
process of the copolymer synthesis.
1H nuclear magnetic resonance (1H NMR)
1H nuclear magnetic resonance spectra were detected by 
a Bruker Avance 400 MHz spectrometer (Billerica, MA, 
USA) with CDCl3 as a solvent.
Fourier transform infrared (FTIR) spectroscopy
Fourier transform infrared spectra of the polymers and 
copolymers were recorded using a Bruker Tensor 27 
FTIR spectrophotometer. The samples were pressed into 
KBr pellets for analysis.
Molecular weight
The molecular weights of the copolymers were measured 
by gel permeation chromatography (GPC), which was 
performed on a Jasco high-performance liquid chroma-
tography (HPLC) system (Tokyo, Japan) equipped with 
a refractive-index detector. Jordi Gel polydivinyl ben-
zene columns with pore sizes of 100, 500, and 1,000  Å 
were employed for determination. The eluent used in this 
experiment was chloroform at a flow rate of 0.5 ml/min. 
Polyethylene glycol was used as the standard for estab-
lishing a calibration curve.
Preparation of micelles
The copolymer micelles of PNiPAAm-b-PCL were pre-
pared using the dialysis method. A solution of diblock 
copolymer (30 mg) was dissolved in DMF (5 ml) and was 
then placed in a dialysis bag with a molecular weight cut-
off of 3,500  Da. Carboplatin (5  mg) was added in DMF 
to prepare the drug-containing nanocarriers if necessary. 
The DMF solution was dialyzed against double-distilled 
water (ddH2O) at room temperature for 24 h. The water 
was replaced every 30 min during the first 3 h.
Critical micelle concentration (CMC)
The CMC of the copolymers was measured by fluores-
cence spectroscopy (Hitachi F-7000, Tokyo, Japan) using 
pyrene as the probe. The pyrene solution (100 μl) in ace-
tone at a concentration 6.1 × 10−5 M was added to a vial. 
After evaporation, the measured quantities of micellar 
solutions with various concentrations of PNiPAAm-b-PCL 
ranging from 1.83 × 10−5 to 0.3 g/l were incorporated into 
the vial. The concentration of pyrene in the micellar solu-
tion was 6.1 × 10−7 M. After equilibration at room tem-
perature overnight, the fluorescence excitation spectra of 
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the final solution were determined at an emission wave-
length of 390  nm. The excitation fluorescence values I334 
and I331, respectively, at 334 and 331 nm, were detected for 
the subsequent measurement of the CMC.
Lower critical solution temperature (LCST)
The LCST of the diblock copolymers was measured by 
detecting the optical transmittance. A UV spectrometer 
(Jasco V-550, Tokyo, Japan) was used by monitoring the 
transmittance of a 500-nm light beam through the copol-
ymer solution at the concentration of a 50-fold CMC. 
The samples were heated at a rate of 0.15°C/min from 25 
to 50°C. The LCST was determined at the temperature at 
which the optical transmittance was 50%.
Average diameter and zeta potential
The mean diameter (z-average) and zeta potential of the 
prepared micelles were detected using a laser-scattering 
method (Nano ZS90, Malvern, Worcestershire, UK). The 
determination was performed at the concentration of a 
50-fold CMC.
Transmission electron microscopy (TEM)
The morphology of PNiPAAm-b-PCL micelles was moni-
tored by Jeol JEM-1400 TEM (Tokyo, Japan). A 10-μl 
of micelle dispersion was pipetted onto a carbon-film-
coated copper grid to form a thin-film specimen and 
stained with 1% phosphotungstic acid. The prepared 
samples were photographed by TEM.
Carboplatin release from micelles
This experiment was conducted with Franz diffusion 
cells. A cellulose membrane with a molecular weight cut-
off of 6,000–8,000  Da (Cellu-Sep® T2, Membrane Filtra-
tion Products, Seguin, TX, USA) was mounted between 
the receptor and the donor. The receptor contained 30% 
ethanol in pH 7.4 buffer with a volume of 5.5  ml. The 
donor (0.5  ml) was loaded with carboplatin-containing 
micelle dispersion or carboplatin in control solution (4% 
DMSO in double-distilled water). Carboplatin concen-
tration in the dispersions was 0.1  mg/ml. The available 
diffusion area for carboplatin was 0.785  cm2. The tem-
perature was set at 25 or 37°C. The 300 μl aliquots of the 
receptor medium were withdrawn at determined inter-
vals. The receptor compartment was immediately added 
to an equal volume of fresh medium. The samples taken 
from the receptor were analyzed by atomic absorption 
spectroscopy (Hitachi Z-5000, Tokyo, Japan) to quantify 
the amount of carboplatin.
Cytotoxicity determined by lactate dehydrogenase (LDH)
The neutrophils from healthy volunteers (20–30  years 
old) were purified using a protocol approved by the 
Institutional Review Board at Chang Gung Memorial 
Hospital. All subjects were required to provide written 
informed consent. Neutrophils were isolated with sedi-
mentation prior to centrifugation in a Ficoll Hypaque 
gradient and hypotonic lysis of erythrocytes. LDH leak-
age from the neutrophils after micelle treatment was 
detected by a commercially available method (Cyto-
Tox 96®, Promega, Madison, WI, USA). Neutrophils 
(6  ×  105  cells/ml) were equilibrated at 37°C for 2  min 
and subsequently treated with copolymer dispersion at 
different concentrations (1.5–48 μg/ml) for 15 min. The 
cytotoxicity was displayed by LDH release in cell-free 
medium as a percentage of the total LDH released. The 
total LDH release was measured by treating 0.1% Triton 
X-100.
Cell viability
Human embryonic kidney cells (293T) and human 
keratinocytes (HaCaT) were seeded in 96-well plates by 
properly-selected culture medium for 24 h. Different vol-
umes of copolymer dispersion were added to the wells 
to make final copolymer concentrations of 1.5, 3, 6, 12, 
and 48 μg/ml. The incubation time of the cells exposed 
to the micelles was 24 h. Tetrazolium salt in isopropanol 
was pipetted into the wells after 24 h. The optical density 
of the dissolved material was determined using a spec-
trophotometer to calculate the viability of the 293T and 
HaCaT cells.
Animals
Male Sprague–Dawley rats (~400  g) were used for the 
in vivo experiments. The experimental protocol was 
received and approved by the Institutional Animal Care 
and Use Committee of Chang Gung University. All ani-
mals were housed and handled according to the institu-
tional guidelines.
Organ bioimaging
The rats were anesthetized using Zoletil® 50 (60 mg/kg). 
The body temperature of the rats was kept at 37°C with 
a heating pad. The control solution or micelle dispersion 
containing DiR (0.05%, w/v) as a fluorescence dye was 
injected into the femoral vein at a volume of 0.25 ml/kg. 
Isoflurane/oxygen was used to maintain the anesthetized 
status. The rats were sacrificed 2  h postinjection. The 
organs were removed from the body and washed with 
saline. The DiR fluorescence in the organs was monitored 
using the Pearl® Impulse imaging system (Li-Cor, Lincoln, 
NE, USA) at near IR wavelength.
Biodistribution of carboplatin
Twelve rats were randomly divided into two groups. The 
rats in each group were injected with the control solution 
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(4% DMSO in ddH2O) or micelles at a carboplatin dose 
of 0.25 mg/kg. The rats were sacrificed 2 h after dosing. 
The brain, lungs, heart, liver, spleen, and kidneys were 
harvested from the body. The organs were weighed and 
suspended in methanol (1  ml) by MagNA Lyser (Roche, 
Indianapolis, IN, USA). The homogenates were centri-
fuged at 10,000×g for 10  min. The supernatant (0.2  ml) 
was taken and then mixed with acetonitrile (0.6 ml). Fol-
lowing a centrifugation at 10,000×g for 10 min, the super-
natants were assessed by atomic absorption spectroscopy.
Statistical analysis
Statistical calculation was performed using an unpaired 
t-test. The post hoc Newman–Keuls test was utilized to 
check the individual differences between the groups. A 
probability of <0.05 was considered significant.
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